Sumbal Jesrani
Rise Above Heart Failure!
Explore potential therapeutic approaches through Chronic Heart Failure Clinical Trials.
Chronic heart failure (CHF) is a long-term, complex disorder, associated with symptoms such as dyspnea, fatigue at rest or during exertion that develops gradually and progressively worsens over time. It is the leading cause of hospitalization and is estimated to affect more than 6 million adults in the United States.
While standard pharmacotherapies improve symptoms and prolong survival, the prognosis for patients with heart failure (HFrEF) is still poor.
Prime Revival Research Institute is conducting Heart Failure Clinical Trials to evaluate the safety and efficacy of a potential study drug in people diagnosed with heart failure (heart failure with reduced ejection fraction or HFrEF).
You may be able to participate if you:
- Are a male or female between 30-85 years
- Have been diagnosed with heart failure (HF) with reduced left ventricular ejection fraction (LVEF)
- Are on a stable dose of renin-angiotensin-aldosterone system (RAAS) or β-blockers for >4 weeks*Additional criteria may apply.
Your doctor will review additional study criteria with you and see if you qualify. If you qualify and decide to participate in the Chronic Heart Failure Clinical Trials, you will receive all study-related care, free of cost.
*You will receive monetary compensation for your time and travel.
*If you think you may be eligible to participate in the Heart Failure Clinical Trials or would like more information, please enter your information in the form so that our research team could see if you qualify and could contact you about the study.
About the Heart Failure Clinical Trials
Prime Revival Research Institute is conducting a clinical trial to evaluate the safety and efficacy of a study drug in people with heart failure, who are on stable, guideline-directed medical therapy for HF.
The goal of the clinical trial is to improve the quality of life by improving cardiac efficiency in people with heart failure, with oral administration of a study drug that has a different mechanism of action from existing drugs. During the study, participants will receive the double-blinded study treatment for 12 weeks (about 3 months). This means that neither you nor the study doctor will know which treatment you receive — it could either be the study drug or the placebo.
The study will consist of a 4-week screening period, a 12-week double-blind treatment period, and a 4-week follow-up. The Heart failure research study is divided into 3 phases:
- Screening period (up to 4 weeks).
- Treatment period (12 weeks)
- Follow-up period (4 weeks)
About Heart Failure
Heart failure with reduced ejection fraction (HFrEF), also known as Systolic Heart failure, is a condition in which the left ventricle of the heart is unable to pump a sufficient amount of blood to meet the body’s needs. This happens when the muscles of the left ventricle work inefficiently, squeezing and pumping some (but not all) of the blood during the systole phase, from the ventricle out to your body. The ejection fraction recorded in individuals with systolic heart failure with a reduced ejection fraction (HFrEF) is 40% or less.
Some of the likely factors that put individuals at risk of heart failure are coronary artery disease, cardiomyopathy, high blood pressure, arrhythmia, mitral regurgitation, and viral myocarditis. The characteristic symptoms commonly associated with systolic heart failure are dyspnea and fatigue, manifested either during exertion or at rest.
According to heart failure guidelines, conventional pharmacological drugs are identified as the first line of therapy, but investigating novel therapies that might improve patient prognosis are desirable.
